A document that you may have missed in your readings.
Cancer survival in five continents: a worldwide population-based study (CONCORD)
Background Cancer survival varies widely between countries. The CONCORD study provides survival estimates for 1·9 million adults (aged 15–99 years) diagnosed with a first, primary, invasive cancer of the breast (women), colon, rectum, or prostate during 1990–94 and followed up to 1999, by use of individual tumour records from 101 population-based cancer registries in 31 countries on five continents. This is, to our knowledge, the first worldwide analysis of cancer survival, with standard quality-control procedures and identical analytic methods for all datasets.
We analysed individual data for almost 2 million adults who were diagnosed with a first, primary, malignant, invasive neoplasm of the breast (women), colon, rectum, or prostate during the period 1990–94 and who had been followed up to ascertain their vital status for at least 5 years after diagnosis until the end of 1999 or later. Data were contributed by 101 population-based cancer registries covering a combined population of almost 300 million persons living in 31 countries
From your article
Percentage of men and women who survived a cancer five years
From the Concord study.
Relative survival at 5 years, age-standardised to the International Cancer Survival Standard weights, ranged from 80% or over in North America, Sweden, Japan, Finland, and Australia to less than 60% in Brazil and Slovakia, and below 40% in Algeria (table 2 and figure 1). Survival in the 24 European countries that contributed to CONCORD was mostly in the range 70–79%.
The pooled estimate of 5-year survival for Canada was 82·5%, with a narrow range from 79·3% in Nova Scotia to 85·4% in British Columbia (table 2 and figure 1). In the USA, 5-year relative survival for all races combined ranged from 78–81% in New York City, New York State, and Louisiana to 89–90% in Hawaii and Seattle, WA (table 2), but most of the estimates were within a fairly narrow range, from 82% to 87% (figure 2).
Survival was lower for blacks than for whites in all 17 populations in the USA for which this could be assessed with race-specific life tables (webfigure 2). The age-adjusted pooled estimate of 5-year survival was 84·7% for whites (range 80–90%) and 70·9% for blacks (table 3).
The study has a lot of information and breaks down cancers into different types out of 31 countries. On one chart it shows Cuba as having the best 5 year survival rate for Woman's breast cancer closely followed by the USA and then Canada with England down at #22, and then for Prostate cancer the USA is at the top of the list with Austria and then Canada following and Cuba at #8 and England #19. And then with Colorectum cancer Cuba is at the top for women's survival and only beat out by Japan in men survival (USA women #3, Canada #4, and men, USA #3 and Canada #6).
In another chart woman breast cancer 5 year survival rate is listed as USA 83·9%, Canada 82·5%.